SCHEMBL23728541

SCHEMBL23728541

CCc1ccnc2c(C(=O)O)cnn12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.53
KDM4E B2RXH2 5/20 0.52
ALDH1A1 P00352 2/20 0.52
TDP1 Q9NUW8 1/20 0.48
LIMK1 P53667 2/20 0.46
MARK2 Q7KZI7 2/20 0.46
MAPK13 O15264 1/20 0.46
MAP2K1 Q02750 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
NR4A3 Q92570 1/20 0.43
TLR8 Q9NR97 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PIM1 P11309 3/20 0.39
MAPK9 P45984 1/20 0.39
DYRK1A Q13627 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GSK3A P49840 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23728564 0.85 HSD11B1 (0.52) HSD11B1KDM4EALDH1A1LIMK1MARK2
SCHEMBL359062 0.79 KDM4E (0.57) HSD11B1KDM4EALDH1A1TDP1LIMK1
SCHEMBL11894609 0.78 KDM4E (0.49) HSD11B1KDM4EALDH1A1TDP1LIMK1
SCHEMBL3172208 0.77 MAPK13 (0.70) KDM4EALDH1A1TDP1LIMK1MARK2
SCHEMBL2462603 0.77 KDM4E (0.57) KDM4EALDH1A1TDP1LIMK1MARK2
SCHEMBL18819891 0.77 KDM4E (0.53) HSD11B1KDM4ELIMK1MARK2MAPK13
SCHEMBL10408157 0.77 KDM4E (0.57) KDM4EALDH1A1TDP1LIMK1MARK2
SCHEMBL11894259 0.77 KDM4E (0.48) HSD11B1KDM4EALDH1A1TDP1LIMK1
SCHEMBL23728533 0.76 KDM4E (0.54) KDM4EALDH1A1TDP1LIMK1MARK2
SCHEMBL7303862 0.76 NR4A3 (0.48) KDM4EALDH1A1TDP1NR4A3TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885KDM4E 190/4885ALDH1A1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.